Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 125 of 198 entries
View as:

Chidamide Combined With VDDT Regimen in the Relapse and Refractory Diffuse Large B Cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT02733380 Org: User:
Start: 05/31/16 End: 05/31/21 Due: 05/31/22

Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Vinorelbine in Trastuzumab-refractory HER2-Positive Breast Cancer.

Phase: N/A Priority: Normal
NCT ID: NCT03947242 Org: User:
Start: 06/01/19 End: 12/30/20 Due: 12/30/21

Go-CHOP as the Frontline Therapy for PTCL

Phase: N/A Priority: Normal
NCT ID: NCT05963347 Org: User:
Start: 08/03/23 End: 07/31/26 Due: 07/31/27

Application of Painting Analysis and Psychotherapy in Children With Bone Tumors

Phase: N/A Priority: Normal
NCT ID: NCT05475938 Org: User:
Start: 10/20/21 End: 05/05/22 Due: 05/05/23

A Single-arm, Prospective Phase Ⅱ Clinical Study of Utidelone Combined with Capecitabine in the Treatment of Active Brain Metastasis of TNBC

Phase: N/A Priority: Normal
NCT ID: NCT06598046 Org: User:
Start: 06/19/24 End: 08/01/26 Due: 08/01/27

PD-1 Antibody Tislelizumab Combined With Dacarbazine in the Treatment of Advanced Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT05466474 Org: User:
Start: 12/30/22 End: 04/30/24 Due: 04/30/25

First-line Treatment for ES-SCLC with Chemotherapy Combined with PD-1/PD-L1 Inhibitor Sequential Thoracic Radiotherapy

Phase: N/A Priority: Normal
NCT ID: NCT06586697 Org: User:
Start: 12/01/23 End: 03/20/26 Due: 03/20/27

Disitamab Vedotin Combined With Sintilimab and XELOX Perioperative Treatment for Resectable Gastric Caner With HER2 Overexpression

Phase: N/A Priority: Normal
NCT ID: NCT06227325 Org: User:
Start: 02/01/24 End: 12/31/25 Due: 12/31/26

Neoadjuvant Chemotherapy Versus Surgery Alone for Esophageal Squamous Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT02395705 Org: User:
Start: 06/30/15 End: 10/31/22 Due: 10/31/23

Application of LARS Ligament in Bone Prosthesis Replacement

Phase: N/A Priority: Normal
NCT ID: NCT05616182 Org: User:
Start: 12/30/24 End: 02/28/32 Due: 02/28/33

Treatment of Dalpiciclib Combined With Pyrotinib for Trastuzumab-sensitive HER2+ Advanced Breast Cancer(DAP-Her-02)

Phase: N/A Priority: Normal
NCT ID: NCT05328440 Org: User:
Start: 05/20/22 End: 01/01/26 Due: 01/01/27

Thoracic Surgery Combined With Intrathoracic Hyperthermic Perfusion for Advanced Lung Cancer / Esophageal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03110939 Org: User:
Start: 03/21/17 End: 04/05/21 Due: 04/05/22

BCMA-CAR-T in Relapsed/Refractory Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT03664661 Org: User:
Start: 04/11/18 End: 04/30/20 Due: 04/30/21

Real-World Effectiveness of Regorafenib in the Treatment of Patients With Metastatic Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05023720 Org: User:
Start: 07/20/21 End: 12/21/22 Due: 12/21/23

An Exploratory Study of Herombopag for Thrombocytopenia Induced by Chemotherapy Combined With Immunotherapy in NSCLC

Phase: N/A Priority: Normal
NCT ID: NCT05252091 Org: User:
Start: 02/20/22 End: 09/20/22 Due: 09/20/23

Apatinib Treatment for Advanced Esophagus Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03170310 Org: User:
Start: 02/21/17 End: 09/21/19 Due: 09/21/20

Axillary Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Patients With Initial cN1 Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06518135 Org: User:
Start: 04/30/24 End: 03/31/28 Due: 03/31/29

Autologous Cytokine-induced Killer Cells Combined Chemotherapy in Advanced Pancreatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03002831 Org: User:
Start: 11/30/16 End: 10/31/19 Due: 10/31/20

Cord Blood Derived CAR-T Cells in Refractory/Relapsed B Cell Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT03881774 Org: User:
Start: 02/27/19 End: 01/31/22 Due: 01/31/23

Evaluating High-dose Furmonertinib with Bevacizumab and Pemetrexed for EGFRm NSCLC with Leptomeningeal Metastasis

Phase: N/A Priority: Normal
NCT ID: NCT06643000 Org: User:
Start: 12/20/24 End: 05/30/25 Due: 05/30/26

Patient-derived Organoid Drug Sensitivity Guided Treatment for Recurrent Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06406660 Org: User:
Start: 04/16/24 End: 06/16/26 Due: 06/16/27

Utidelone Plus Bevacizumab for Advanced Breast Cancer With Brain Metastases

Phase: N/A Priority: Normal
NCT ID: NCT05357417 Org: User:
Start: 04/29/22 End: 05/31/24 Due: 05/31/25

Study of Donafenib Combined With Tislelizumab in the Adjuvant Treatment of Primary HCC With High Risk of Recurrence

Phase: N/A Priority: Normal
NCT ID: NCT05545124 Org: User:
Start: 11/30/22 End: 11/30/24 Due: 11/30/25

Camrelizumab Combined With Apatinib for Advanced Gastric or Esophagogastric Adenocarcinoma

Phase: N/A Priority: Normal
NCT ID: NCT04948125 Org: User:
Start: 04/28/21 End: 08/03/23 Due: 08/03/24

A Study of Monosialic Gangliosides to Prevent Albumin-bound Paclitaxel Neurotoxicity

Phase: N/A Priority: Normal
NCT ID: NCT04222790 Org: User:
Start: 08/28/20 End: 04/21/22 Due: 04/21/23